MEIRAGTX HOLDINGS PLC Share Price Today: Live Updates & Key Insights

MEIRAGTX HOLDINGS PLC share price today is $7.21, up -2.04%. The stock opened at $7.31 against the previous close of $7.35, with an intraday high of $7.37 and low of $7.16.

MEIRAGTX HOLDINGS PLC Share Price Chart

MEIRAGTX HOLDINGS PLC

us-stock
To Invest in {{usstockname}}
us-stock

MEIRAGTX HOLDINGS PLC Share Price Performance

$7.21 -0.0204(-2.04%) MGTX at 23 Mar 2026 02:16 PM Biotechnology
Lowest Today 7.16
Highest Today 7.37
Today’s Open 7.31
Prev. Close 7.35
52 Week High 9.73
52 Week Low 4.55
Day’s Range: Low 7.16 High 7.37
52-Week Range: Low 4.55 High 9.73
1 day return -
1 Week return -6.37
1 month return -4.25
3 month return -13.04
6 month return -11.11
1 year return -6.12
3 year return +39.53
5 year return -54.71
10 year return -

MEIRAGTX HOLDINGS PLC Institutional Holdings

Perceptive Advisors LLC 15.69

Sanofi 15.15

Johnson & Johnson 8.25

Rubric Capital Management LP 7.67

Adage Capital Partners Gp LLC 4.97

Prosight Management, LP 3.99

Millennium Management LLC 3.95

BlackRock Inc 3.45

683 Capital Management LLC 3.18

Knoll Capital Management LP 1.55

Morgan Stanley - Brokerage Accounts 1.54

iShares Russell 2000 ETF 1.38

Erste Asset Management GmbH 0.98

State Street Corp 0.85

22NW, LP 0.73

Geode Capital Management, LLC 0.71

Long Focus Capital Management, LLC 0.65

Vanguard Group Inc 0.61

Fidelity Small Cap Index 0.55

iShares Biotechnology ETF 0.54

Opaleye Management Inc 0.49

D. E. Shaw & Co LP 0.47

J. Goldman & Co LP 0.40

iShares Russell 2000 Growth ETF 0.35

State St Russell Sm/Mid Cp® Indx SL Cl I 0.35

Vanguard Russell 2000 ETF 0.27

Royce Smaller-Companies Growth Svc 0.22

State St Russell Sm Cap® Indx SL Cl I 0.17

Vanguard Health Care ETF 0.16

iShares Micro-Cap ETF 0.15

Schwab Small Cap Index 0.14

iShares Russell 2000 Value ETF 0.13

NT R2000 Index Fund - NL 0.12

AZ Equity Biotechnology A-AZ EUR Acc 0.12

Galileo - Biotech Innovation Fund S USD 0.11

Stt Strt SPDR® Russell2000 US SmCapETF 0.10

NT R2000 Index Fund - DC - NL - 3 0.10

Russell Inv Tax-Managed US Mid&Sm Cap S 0.10

Nuveen Equity Index R6 0.09

iShares Russell 2000 Small-Cap Idx Instl 0.09

MEIRAGTX HOLDINGS PLC Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

MEIRAGTX HOLDINGS PLC Fundamentals

Market Cap 579.53 M

PB Ratio 225.3073

PE Ratio 0.0

Enterprise Value 652.75 M

Total Assets 269.75 M

Volume 443359

MEIRAGTX HOLDINGS PLC Company Financials

Annual Revenue FY23:6689000 6.7M, FY22:15920000 15.9M, FY21:37701000 37.7M, FY20:15562985 15.6M, FY19:13291956 13.3M

Annual Profit FY23:null 0.0M, FY22:15920000 15.9M, FY21:37701000 37.7M, FY20:15562985 15.6M, FY19:13291956 13.3M

Annual Net worth FY23:-131555000 -131.6M, FY22:-142875000 -142.9M, FY21:-71976000 -72.0M, FY20:-53959581 -54.0M, FY19:-52556287 -52.6M

Quarterly Revenue Q3/2025:410000 0.4M, Q2/2025:3691000 3.7M, Q1/2025:1926000 1.9M, Q3/2024:10910000 10.9M, Q2/2024:282000 0.3M

Quarterly Profit Q3/2025:97000 0.1M, Q2/2025:1015000 1.0M, Q1/2025:548000 0.5M, Q3/2024:-1075000 -1.1M, Q2/2024:-2940000 -2.9M

Quarterly Net worth Q3/2025:-50513000 -50.5M, Q2/2025:-38795000 -38.8M, Q1/2025:-39981000 -40.0M, Q3/2024:-39330000 -39.3M, Q2/2024:-48620000 -48.6M

About MEIRAGTX HOLDINGS PLC & investment objective

Company Information MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Organisation Biotechnology

Employees 409

Industry Biotechnology

CEO Dr. Alexandria Forbes Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

MEIRAGTX HOLDINGS PLC FAQs

What is the share price of MEIRAGTX HOLDINGS PLC today?

The current share price of MEIRAGTX HOLDINGS PLC is $7.21.

Can I buy MEIRAGTX HOLDINGS PLC shares in India?

Yes, Indian investors can buy MEIRAGTX HOLDINGS PLC shares by opening an international trading and demat account with Motilal Oswal.

How to buy MEIRAGTX HOLDINGS PLC shares in India?

You can easily invest in MEIRAGTX HOLDINGS PLC shares from India by:

Can I buy fractional shares of MEIRAGTX HOLDINGS PLC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of MEIRAGTX HOLDINGS PLC?

MEIRAGTX HOLDINGS PLC has a market cap of $579.53 M.

In which sector does MEIRAGTX HOLDINGS PLC belong?

MEIRAGTX HOLDINGS PLC operates in the Biotechnology sector.

What documents are required to invest in MEIRAGTX HOLDINGS PLC stocks?

To invest, you typically need:

What is the PE and PB ratio of MEIRAGTX HOLDINGS PLC?

The PE ratio of MEIRAGTX HOLDINGS PLC is N/A and the PB ratio is 225.31.